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Purpose: The present study was designed to determine the association of polymorphisms of the DNA repair genes X-ray
cross-complementing group 1 (XRCC1) (c.1316G>A [rs25487]) and xeroderma pigmentosum complementation group D
(XPD) (c.2298A>C [rs13181]) with primary open-angle glaucoma (POAG) and primary closed-angle glaucoma (PCAG).
Methods: In this prospective case-control study, polymerase chain reaction-restriction fragment length polymorphism
analysis was used to study the association of XRCC1 and XPD with 160 POAG patients, 163 PCAG patients, and 193
unaffected controls.
Results: XRCC1 rs25487 was found to be significantly associated specifically with male POAG patients (χ2=13.2
[p=0.001]), only for the dominant model (odds ratio [OR]=2.65 [95% confidence interval [CI]=1.44–4.85], p<0.005). In
addition XPD rs13181 was also found to be associated with male POAG patients (χ2=12.1 [p<0.005]), for both dominant
(OR=2.44 [95% CI=1.33–4.47], p<0.005) as well as recessive model (OR=3.62 [95% CI=1.45–9.01], p<0.01). Combined
genotypes of both the genes revealed that the heterozygote AC/GA was significantly associated with the male POAG
patients (z=3.00 [p<0.001]). The AA/GG genotype was present at a higher frequency in the male controls and the AA/
GA in the female controls and could thus have a protective role in males and females, respectively.
Conclusions: We postulate that defects in the DNA repair genes XRCC1 and XPD may possibly be associated with the
progression of POAG in male patients of Pakistani origin.
Glaucoma is a leading cause of irreversible blindness,
characterized by degeneration of the retinal ganglion cells and
optic nerve damage. Among the two common clinical types
primary open angle glaucoma (POAG) is the most prevalent
form, which is characterized by an obstruction of the aqueous
humor  pathway  as  a  result  of  trabecular  meshwork
degeneration or decay. The other form primary close angle
glaucoma  (PCAG)  is  characterized  by  closure  of  angle
between the iris and trabecular meshwork, mainly because of
anatomic abnormalities. Although the etiology of glaucoma
is not fully understood, there is strong evidence to suggest that
it is caused by a combination of environmental and genetic
factors [1].
Several  studies  support  the  involvement  of  oxidative
damage  to  DNA  as  a  common  factor  of  glaucomatous
neurodegeneration,  which  occurs  in  different  subcellular
compartments of the retinal ganglion cells [2-4]. Many DNA
repair  genes  and  their  polymorphisms  including  the
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Xeroderma pigmentosum complementation group D (XPD,
also known as Excision Repair Cross-complementation group
2 [ERCC2]), and the X-ray cross-complementing group 1
(XRCC1) have been reported to be associated with several
different  diseases  including  glaucoma,  which  have  been
shown to be dependent upon the genetics and ethnicity of the
individuals or environmental factors [5].
XRCC1 on chromosome 19q13.2 encodes a multi-domain
protein that interacts with nicked DNA and is involved in
single-strand breaks and base excision repair (BER) pathway
in response to DNA damage caused by ionizing radiation,
alkylating agents and oxidation. Different XRCC1 mutations
have been shown to disrupt the function of the protein by
affecting its binding to the substrate or by introducing changes
in the catalytic domain [6]. A single nucleotide polymorphism
(SNP; c.1316G>A; p.Arg399Gln, rs25487), located near the
breast cancer C-terminal domain (BRCT), is involved in cell
cycle checkpoint functions that are initiated in response to
DNA damage. This BRCT domain interacts with the poly-
ADP-ribose  polymerase  binding  domain  of  Poly  (ADP-
ribose) polymerase-1, which is an enzyme involved in the
BER pathway [7]. Therefore any change in the structure of
BRCT has the potential to lead to defects in the detection of
the  DNA  damage  and  hence  the  activation  of  the  BER
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1153pathway. Although no direct functional evidence is available
that  the  variant  c.1316A  allele  interrupts  the  interaction
between BRCT and Poly (ADP-ribose) polymerase-1, but
indirect  functional  analysis  using  biomarkers,  such  as
chromosomal aberrations, have shown that cancer patients
with the c.1316A allele have a significantly higher number of
chromosomal  aberrations  (such  as  deletions)  and  greater
number of DNA adducts as compared to individuals with wild
type c.1316G allele, indicative of defects in the BER pathway
[8,9].
XPD encodes an ATP-dependent DNA helicase present
1.8 Mb downstream of XRCC1 on chromosome 19q13.3, it is
an important component of the Transcription Factor IIH that
is involved in nucleotide excision repair (NER) of UV induced
damage and removal of bulky adducts [5]. Genetic variations
in XPD are associated with defects in the NER mechanism
[10] resulting in autosomal recessive DNA repair disorders.
Two  SNPs  in  XPD,  p.Asp312Asn  (rs1799793)  and
p.Lys751Gln (rs13181), have been shown to be involved in
susceptibility to various types of cancer in addition to various
inherited and age related diseases [7,11]. The rs13181 affects
an ATP-binding site of XPD and destroys its helicase activity,
which  is  important  for  NER,  but  does  not  affect  its
transcriptional  activity  [12].  The  lysine  at  codon  751  is
assumed to be involved in interactions with the substrate of
XPD,  thus  any  substitution  at  this  residue  may  produce
changes in its function which can impair the DNA repair
capacity [13].
Up to the present date there is no data available that shows
a significant association of the polymorphisms of DNA repair
genes with glaucoma in any specific ethnic group [14]. The
aim  of  the  present  study  was  therefore  to  investigate  the
relationship between polymorphisms of the DNA repair genes
and two different forms of glaucoma in the Punjabi Pakistani
population.  Our  study  is  the  first  from  Pakistan  to  report
ethnic-based  associations  of  the  XRCC1  and  XPD
polymorphisms with male POAG patients.
METHODS
Patient selection criteria: This study conforms to the tenants
of the Helsinki declaration and has been approved by the
Departmental Review and Ethics Committee. All subjects
were  briefed  about  the  study  in  their  local  language  and
informed  written  consent  was  obtained  from  them  before
obtaining their blood samples. The study group consisted of
Punjabi’s which are the major ethnic group of Pakistan. The
affected arm was composed of 323 Punjabi patients consisting
of 160 POAG (80 males, 80 females) and 163 PCAG cases
(81 males, 82 females), in addition DNA samples of 193
unaffected  (101  males,  92  females)  age  and  sex  matched
Punjabi control individuals were also studied. The inclusion
criteria for patients/controls, clinical examination, as well as
collection  and  processing  of  the  whole  blood  have  been
described previously [15]. In addition to the isolated glaucoma
patients, 9 Punjabi families (29 patients, 68 unaffected) of
congenital POAG were also screened to study the association
of the two SNPs in these families. Briefly, blood samples from
controls,  patients  and  family  members  were  collected  in
EDTA  tubes  and  genomic  DNA  was  extracted  by  a
conventional phenol chloroform method [16].
Polymerase chain reaction (PCR) amplification of genomic
DNA:  The  XRCC1  codon  399  and  XPD  codon  751
polymorphisms were detected by PCR-RFLP. A 242 base pair
(bp)  fragment  containing  the  polymorphism  rs25487  (c.
1316G>A; p.Arg399Gln) in exon 10 of the XRCC1 gene was
amplified using the primers: 5′-CCC CAA GTA CAG CCA
GGT C-3′ (forward) and 5′-TGT CCC GCT CCT CTC AGT
AG-3′  (reverse).  A  436-bp  fragment  containing  the
polymorphism rs13181 (c.2298A>C; p.Lys751Gln) in exon
23 of the XPD gene was amplified using the primers 5′-GCC
CGC TCT GGA TTA TAC G-3′(forward) and 5′-CTA TCA
TCT CCT GGC CCC C-3′ (reverse). The 25 µl-PCR reaction
for each polymorphism contained 1× PCR buffer, 1.5 mM
MgCl2 (Fermentas, Burlington, Ontario), 10 pmol of each
primer,  0.2  mM  deoxy  nucleotide  triphosphates  (dNTPs;
Fermentas,  Burlington,  Ontario),  1  U  Taq  polymerase
(Biotools,  Madrid,  Spain)  and  50  ng  genomic  DNA  as
template. The PCR thermal cycling profile consisted of an
initial denaturation at 95 °C for 5 min followed by 35 cycles
of 1 min DNA denaturation at 95 °C, primer annealing for 45
s at 60 °C, 1 min extension at 72 °C, followed by one cycle of
a final extension step for 7 min at 72 °C. The amplifications
were performed with an Applied BioSystem Gene Amp® PCR
system 2700 (Foster City, CA).
Restriction fragment length polymorphism (RFLP) analysis
of  XRCC1:  The  PCR  products  were  digested  with  MspI
restriction enzyme (Fermentas, Burlington, Ontario) at 37 °C
overnight, followed by electrophoretic separation on 2.5%
agarose gels, along with a 100 bp DNA ladder (Invitrogen Inc.,
Carlsbad, CA). The “A” allele of the polymorphism rs25487
degenerates a MspI restriction site, resulting in two fragments
of 148 and 94 bp for the GG genotype, three fragments of 242,
148, and 94 bp of the AG genotype, and a single fragment of
242 bp for the AA genotype (Figure 1).
RFLP analysis of XPD: The PCR amplified products were
digested with PstI restriction enzyme (Fermentas) overnight
at 37 °C and the fragments were resolved on 4% agarose gel.
The “C” allele of the polymorphism rs13181 creates a PstI
restriction site. The AA genotype results in two fragments of
290 and 146 bp, four fragments of 290, 227, 146, and 63 bp
for the AC genotype, and three fragments of 227, 146, and 63
bp for the CC genotype (Figure 1).
Sequence analysis of XRCC1 and XPD genotypes: To validate
the  RFLP  results  5  random  samples  of  each  genotype  of
rs25487 (n=15) and rs13181 (n=15) were sequenced using the
primers described above for the PCR amplification of these
SNP’s (Figure 2A-F).
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1154Statistical  analysis:  The  demographic  features  (age,  Intra
Ocular  Pressure  [IOP],  and  Cup  to  Disk  Ratio  [CDR]),
genotype, and allele distribution of both patient and controls
were analyzed by using SPSS (ver. 16; SPSS, Chicago, Il) and
the level of significance of the clinical parameters were tested
using Minitab (ver. 15; Minitab, Chicago, Il). The genotype
and  allele  frequency  differences  between  POAG,  PCAG,
controls,  and  affected/non-affected  family  members  were
compared by chi square (χ2) and/or z tests, a p-value <0.05
was considered to be statistically significant.
RESULTS
In the present study the mean age of controls was 39.7±11.9
and 41.3±13.7 for POAG, and 43.6±15.8 years in case of
PCAG patients, there being no  statistically  significant dif-
ference in the ages of the three groups. In most of the patients
the disease was diagnosed at an advance stage, therefore an
early onset of the disease cannot be precluded. In all the
patients  there  was  no  evidence  of  systemic  diseases  like
diabetes, hypertension, etc. in addition the development of
secondary glaucoma due to some other eye anomaly was also
ruled  out.  The  mean  IOP  in  the  controls  was
13.70±1.86  mmHg,  which  was  significantly  higher  in  the
POAG  and  PCAG  patients  (26.00±9.27  mmHg  and
26.50±10.80 mmHg, respectively, p<0.001). Similarly, the
CDR  in  the  control  group  was  0.30±0.11,  which  was
significantly larger in the POAG and PCAG patients (0.83±.
30 and 0.65±.23, respectively, p<0.001).
XRCC1  genotyping:  For  the  POAG  patients  (Male
+Female) there was no significant difference in the overall
genotype (GG, GA, and AA) distribution as compared to Male
+Female control group (χ2=5.69 [p>0.05]; Table 1), although
the frequency of the GA genotype was significantly higher in
the patients (z=2.29 [p<0.05]). However, when the data were
analyzed  along  the  lines  of  gender  a  highly  significant
difference was observed between the genotype distribution of
the  male  POAG  and  control  samples  (χ2=13.2  [p=0.001];
Table 1), while no significant difference was observed in the
case  of  the  females  (χ2=2.93  [p>0.05];  Table  1).  The
difference  in  the  genotype  frequency  of  the  male  POAG
patients was significant only under a dominant model (odds
ratio [OR]=2.65 [95% confidence interval [CI]=1.44–4.85],
p<0.005). As opposed to this analysis of the PCAG samples
revealed  no  significant  difference  in  the  overall  genotype
distribution  of  Male+Female  as  compared  to  the  controls
(χ2=0.25  [p>0.05]),  as  well  as  when  the  samples  were
distributed along the lines of gender (Table 1).
The frequency of the risk allele “A” was 39% in the male
POAG patients, which was significantly higher from the 29%
in  the  male  controls  (χ2=4.56  [p<0.05],  OR=1.61  [95%
CI=1.04–2.5], p<0.05; Table 1).
XPD genotyping: The overall genotype (AA, AC, and
CC) distribution in the POAG (Male+Female) and controls
was significantly different from each other (χ2=8.75 [p=0.01];
Table  2),  which  was  statistically  significant  under  the
dominant  model  only  (OR=1.89  [95%  CI=1.23–2.92],
p=0.005).  As  opposed  to  this  no  significant  difference
between  the  genotype  frequencies  of  PCAG  and  control
subjects was found (χ2=5.68 [p>0.05]).
When the POAG data were split along the lines of gender,
only  the  male  genotype  distribution  was  found  to  be
significantly different from the controls (χ2=12.1 [p<0.005]),
which was significant under the dominant model (OR=2.44
[95% CI=1.33–4.47], p<0.005) as well as the recessive model
(OR=3.62 [95% CI=1.45–9.01], p<0.01).
Compared  to  the  male  control  individuals  (26%)  the
frequency of the risk allele “C” was significantly higher in the
POAG patients (44%) (χ2=12.96 [p<0.001], OR=2.24 [95%
CI=1.44–3.49], p<0.001).
Combined Genotypes of XRCC1 and XPD genes: The
combined genotypes of XPD and XRCC1 of the controls (Male
Figure 1. Agarose gel electrophoresis of the polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) analysis
of XPD and XRCC1. (Lanes 1–5) PstI digested fragments of exon 23 c.2298A>C XPD SNP. (Lane 1) AA genotype consisting of two fragments;
290 and 146 bp. (Lanes 2, 3, and 5) AC genotype consisting of four fragments; 290, 227, 146 and 63 bp. (Lane 4) CC genotype consisting of
three fragments; 227, 146, and 63 bp. (Lanes 6–9) MspI digested fragments of exon 10 c.1316G>A XRCC1 SNP. (Lane 7) GG genotype
consisting of two fragments; 148 and 94 bp. (Lanes 6 and 8) AG genotype consisting of three fragments; 242, 148, and 94 bp. (Lane 9) AA
genotype consisting of an undigested fragment of 242 bp.
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1155+Female)  was  significantly  different  in  case  of  POAG
(χ2=20.44  [p=0.01])  and  also  in  the  case  of  male  POAG
patients  (χ2=27.04  [p<0.001]),  but  not  for  female  POAG
patients (χ2=13.01 [p>0.05]) or for any distribution in the case
of PCAG. In addition the combined genotype, AC/GA of the
POAG  patients  (Male+Female)  when  compared  to  the
controls was found to be present at a significantly higher
frequency (z=3.42 [p<0.001], which was solely because of the
significantly higher frequency of AC/GA in the male patients
(z=3.00 [p<0.001]) and not because of the female patients
(z=1.82 [p>0.05]; Table 3), though the female patients AC/
GA frequency was greater than the female controls (24%
versus 13%) but not at a statistically significant level. The
combined  genotypes  AA/GG,  was  present  at  a  higher
frequency  in  the  controls  (Male+Female)  as  compared  to
POAG patients (Male+Female; z=2.14, [p<0.05]), which was
solely  because  of  the  higher  frequency  of  this  combined
genotype in the male controls (z=3.12 [p<0.001]). While the
AA/GA combined genotype was present at a higher frequency
in the female controls as compared to female POAG and
PCAG  samples  (z=2.17  [p<0.05]  and  z=2.24  [p<0.05],
respectively).
In  addition  to  the  isolated  glaucoma  samples  the
genotype,  allele  and  combined  genotype  data  were  also
obtained of 9 POAG Punjabi families consisting of 29 affected
(19  male,  10  female)  and  68  non-affected  (33  male,  35
female). As in the sporadic cases the combined genotype AC/
GA was found at a higher frequency in the males from the
affected families (26%) as compared to the random control
population  (14%)  but  this  difference  was  statistically  not
Figure 2. Sequence chromatograms of
the  region  of  XRCC1  and  XPD
containing the respective SNP’s. A-C:
XRCC1  c.1316G>A  (p.Arg399Gln)
variants,  homozygous  GG  (A),
heterozygous GA (B), and homozygous
AA  (C).  D-F:  XPD  c.2298A>C
(p.Lys751Gln)  variants,  homozygous
AA  (D),  heterozygous  AC  (E),  and
homozygous CC (F).
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1159significant (z=1.3 [p>0.05]; data not shown). As opposed to
this the combined genotype AA/GG was not found in any of
the affected male in the families, which when compared with
the healthy control males 35% distribution was statistically
significant (z=3.11 [p=0.001]). The AA/GA genotype was
also  present  at  a  higher  frequency  in  the  female  control
population (21%) as compared to the female patients in the
families (10%), though this was not statistically significant
(z=0.8 [p>0.05]), this genotype was present at a particularly
higher frequency in the non-affected females of one family
(Figure 3).
Of  the  15  XRCC1  and  15  XPD  samples  that  were
sequenced all of the sequence data matched with the RFLP
results thus validating the latter data (Figure 2).
DISCUSSION
The  integrity  of  the  genome  is  continuously  challenged
exogenously and endogenously by DNA damaging agents,
which induce a wide variety of lesions in the DNA including
single  and  double  strand  breaks,  oxidative  lesions  and
pyrimidine dimer formation [4]. These lesions are efficiently
repaired by several pathways that include BER and NER
mechanisms,  which  are  regulated  by  DNA  repair  genes
[17-19]. Of these, BER is believed to be the major pathway
for  repairing  deaminated  bases  and  bases  with  oxidative
damage caused by reactive oxygen species, BER can also be
involved in repairing alkylated bases [20]. As opposed to this
the NER pathway is involved in removing short segments of
nucleotides containing damaged bases [21].
XRCC1,  a  component  of  the  BER  cascade  acts  as  a
scaffold  for  other  enzymes  e.g.,  DNA  ligase,  DNA
polymerase, and poly ADP-ribose polymerase (a zinc finger
containing enzyme that detects DNA strand breaks) [22]. Due
to its central role in the BER pathway, amino acid changes in
XRCC1  can  have  detrimental  effects  on  its  activity  and
subsequently on the BER mechanism. Similarly XPD has also
been shown to play a vital role in the NER pathway and thus
any  non-synonymous  amino  acid  changes  in  XPD  can
potentially result in a defective NER mechanism [10].
Figure  3.  Pedigree  of  the  congenital
primary open angle glaucoma (POAG)
family. Normal females are represented
by circles and males by squares. Filled
squares  represent  affected  males.
Deceased  individuals  are  designated
with a slanting line across the symbol.
XPD and XRCC1 genotypes are shown
for each genotyped individual and the
protective  genotype  (AA/GA)  in  the
females is indicated with green letters.
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1160Unal  et  al.  [23]  reported  XRCC1  and  XPD
polymorphisms to be associated with cataract. In diseases
such as glaucoma, oxidative stress (which could be caused by
raised IOP in the eye) has been shown to increase damage to
the DNA and other macromolecules [23]. Elevated IOP is the
prime  characteristic  of  PCAG  [24]  whereas  degenerative
changes in the trabecular meshwork due to oxidative DNA
damage is a major contributing factor in the progression of
POAG [2]. If the oxidative stress induced DNA damage in
PCAG and POAG remains unchecked, due to failure of the
repair mechanism, it would result in enhanced DNA damage
which might lead to neurodegeneration of the optic nerve [3,
25,26].
Au et al. [27] have previously reported that due to DNA
repair defects there was an increase in the risk of chromosomal
aberrations  in  individuals  who  were  heterozygous  or
homozygous  for  the  derived  alleles  of  p.Arg399Gln  and
p.Lys751Gln, this phenomenon was also observed when the
combined genotypes of these individuals were studied. To
date  there  is  no  documented  evidence  that  shows  an
association  of  the  XRCC1  polymorphism  rs25487  with
glaucoma [14]. In the current study the association of the
XRCC1 polymorphism with only the male POAG patients can
probably be attributed to the significantly higher proportion
of the GA genotype in patients as compared to controls. We
therefore  postulate  that  in  our  study  population  XRCC1 
rs25487 has a gender specific association only with male
POAG  patients.  We  propose  that  although  the  XRCC1
polymorphisms  might  not  directly  participate  in  causing
glaucoma but it can act as a hypomorph and thus could be
involved in accelerating the progression of the DNA damage
in the latter stages of the disease by hindering the DNA repair
mechanism in male patients. This is in agreement with the
observation that oxidative stress affects the optic nerve [25,
26],  which  could  possibly  be  via  a  stress  induced  DNA
damage mechanism where the damage is not corrected timely
due to a defective BER pathway.
Guven  et  al.  [14]  did  not  observe  an  association  of
XRCC1 or XPD polymorphisms with glaucoma in the Turkish
population, which was attributed to small sample size and lack
of ethnic homogeneity by the authors. In addition till date all
the association studies of XRCC1 or XPD polymorphisms
with glaucoma have not analyzed the data along the lines of
gender or ethnic background. We have not only studied an
ethnically pure Punjabi population, which comprises roughly
60% of the total Pakistani population but have also analyzed
the data along the lines of gender and found an association of
XRCC1 rs25487 and XPD rs13181 with male POAG patients.
One of the possible reasons for this gender specific association
could lie in the life style of the Punjabi’s, where 80% of the
population  are  farmers  and  live  in  rural  areas.  Being  an
underdeveloped country antiquated methods of farming are
still in practice in Punjab where mainly the males do most of
the labor intensive outdoor work, this results in a higher degree
of exposure of the males to ambient sunlight and temperature.
Such exposures have been shown to be one of the etiological
factors  causing  age  related  ocular  diseases  like  cataract,
pterygium and macular degeneration [27]. We thus believe
that the higher susceptibility of the Punjabi males toward the
development of the disease, as compared to the females who
mostly remain indoors, is because of the higher exposure of
the males to UV induced damage from the sunlight.
Functional  analysis  conducted  by  Lunn  et  al.  [28]
provides an insight into the potential association of these SNPs
with  disease  and  hence  supports  our  results,  the  authors
demonstrated that sequence alterations, particularly at codon
751 of the XPD, may alter the protein product resulting in
suboptimal repair of X-ray induced DNA damage. Moreover
it has also been reported by Lehmann et al. [10] that mutations
in XPD disrupt its enzymatic functions and cause defects in
NER. We therefore hypothesize that the association of the
XPD polymorphism with POAG could be due to a defective
NER pathway that failed to repair the DNA damage caused
by oxidative stress.
The  combined  genotype  data  revealed  a  significant
association of the different combinations with POAG as well
as PCAG but in a gender specific manner. The association of
the  AC/GA  combined  heterozygotes  with  male  POAG
patients  is  probably  because  of  the  presence  of  a  higher
number of XRCC1 heterozygotes (i.e., G/A) in POAG and not
because of the AC heterozygotes of XPD. This combined
genotype is also found to be present at a higher frequency in
the affected males from the families, though the difference is
statistically non-significant but that is probably due to the
smaller sample size of the affected males in the families.
Au  et  al.  [9],  in  their  functional  characterization  of
XRCC1 and XPD SNP’s showed that the variant genotype of
the XRCC1 might only interact with variant alleles of the other
factors of BER pathways, but not with the variant genotype
of XPD that belongs to the NER pathway.
They  also  showed  that  the  ancestral  XRCC1  (A)  and
XPD (G) as well as the ancestral combined genotypes (AA/
GG) were protective in nature. In our study this association
seems to be a male specific phenomenon as the ancestral
combined  genotype  (AA/GG)  is  present  at  a  much  lower
frequency in the female controls as compared to the male
controls. In the latter group this combined genotype seems to
have a protective role against the development of glaucoma
as  it  is  present  at  a  higher  frequency  in  the  controls  as
compared to the patients. This combined genotype also seems
to play a role in providing protection to the males in the
families as none of the patients had this combined genotype.
Whereas in the case of sporadic female patients the combined
genotype AA/GA seems to play a protective role, which is
also the case in females from the families, particularly in one
family in which this genotype was exclusively present in the
non-affected females (Figure 3).
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1161To validate these results in other populations, it must be
kept in mind that any disease susceptibility or protective role
these  combined  genotypes  play  could  only  be  cross
comparable  in  different  populations  if  similarly  elevated
genotype frequencies are seen in the glaucoma patients in
those populations as compared to normal control individuals.
In summary, our study is the first report that shows an
association between the XRCC1 rs25487 and XPD rs13181
polymorphisms in Pakistani male primary glaucoma patients
belonging to the dominant ethnic Punjabi group. We propose
that  defects  in  the  BER  and  NER  pathway  are  probably
associated with POAG in a gender and ethnic group specific
manner.  In  addition  we  find  that  the  AC/GA  combined
genotypes  might  be  associated  with  increased  risk  for
chromosomal damage that could be due to the reduced DNA
repair functions or selective population association of these
polymorphisms with the disease in the Pakistani Punjabi male
patients and the AA/GG genotype seems to have a protective
role against POAG in Punjabi male patients, while the AA/
GA  genotype  is  protective  in  Punjabi  female  POAG  and
PCAG patients.
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